Current Challenges for IDO2 as Target in Cancer Immunotherapy.


Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2021
Historique:
received: 12 03 2021
accepted: 01 04 2021
entrez: 10 5 2021
pubmed: 11 5 2021
medline: 26 10 2021
Statut: epublish

Résumé

Immune checkpoint inhibitors have revolutionized the clinical approach of untreatable tumors and brought a breath of fresh air in cancer immunotherapy. However, the therapeutic effects of these drugs only cover a minority of patients and alternative immunotherapeutic targets are required. Metabolism of l-tryptophan (Trp)

Identifiants

pubmed: 33968089
doi: 10.3389/fimmu.2021.679953
pmc: PMC8097162
doi:

Substances chimiques

Antineoplastic Agents, Immunological 0
Biomarkers, Tumor 0
Enzyme Inhibitors 0
IDO2 protein, human 0
Indoleamine-Pyrrole 2,3,-Dioxygenase 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

679953

Informations de copyright

Copyright © 2021 Mondanelli, Mandarano, Belladonna, Suvieri, Pelliccia, Bellezza, Sidoni, Carvalho, Grohmann and Volpi.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Immunol Rev. 2010 Jul;236:243-64
pubmed: 20636821
Proc Natl Acad Sci U S A. 2010 Nov 16;107(46):19961-6
pubmed: 21041655
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Gene. 2007 Jul 1;396(1):203-13
pubmed: 17499941
Oncoimmunology. 2014 Dec 15;3(10):e957994
pubmed: 25941578
Front Immunol. 2014 Nov 20;5:585
pubmed: 25477879
Curr Opin Struct Biol. 2017 Dec;47:95-104
pubmed: 28787627
J Immunol. 2010 Sep 15;185(6):3190-8
pubmed: 20720200
Clin Cancer Res. 2019 Jan 15;25(2):724-734
pubmed: 30266763
J Immunol. 2016 Jun 1;196(11):4487-97
pubmed: 27183624
Nat Immunol. 2016 Feb;17(2):132-9
pubmed: 26784254
Sci Signal. 2019 Aug 13;12(594):
pubmed: 31409758
Front Immunol. 2020 Jun 16;11:1185
pubmed: 32612606
FEBS J. 2020 Oct;287(19):4300-4309
pubmed: 32889786
Nat Immunol. 2011 Jul 31;12(9):870-8
pubmed: 21804557
Int J Tryptophan Res. 2017 Oct 09;10:1178646917735098
pubmed: 29051706
J Cell Mol Med. 2017 Jan;21(1):165-176
pubmed: 27696702
Nature. 2016 Mar 3;531(7592):47-52
pubmed: 26909576
Amino Acids. 2010 Jul;39(2):565-78
pubmed: 20140689
Int J Mol Sci. 2020 Aug 01;21(15):
pubmed: 32752186
EMBO Rep. 2020 Dec 3;21(12):e49756
pubmed: 33159421
Lancet Oncol. 2019 Aug;20(8):1083-1097
pubmed: 31221619
World J Gastrointest Oncol. 2020 Feb 15;12(2):173-181
pubmed: 32104548
Blood. 2008 Feb 15;111(4):2152-4
pubmed: 18045970
J Immunol. 2014 Mar 1;192(5):2082-2090
pubmed: 24489090
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Front Immunol. 2020 May 27;11:839
pubmed: 32536910
Cancer Sci. 2019 Oct;110(10):3061-3067
pubmed: 31444833
Eur J Med Chem. 2019 Jan 15;162:455-464
pubmed: 30469041
Sci Rep. 2018 Oct 29;8(1):15917
pubmed: 30374077
J Thorac Oncol. 2011 Feb;6(2):244-85
pubmed: 21252716
Nat Rev Immunol. 2004 Oct;4(10):762-74
pubmed: 15459668
Curr Opin Pharmacol. 2017 Aug;35:30-39
pubmed: 28554057
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
J Neurooncol. 2018 Sep;139(2):239-249
pubmed: 29667084
Cancer Res. 2017 Dec 15;77(24):6795-6811
pubmed: 29247038
Oncotarget. 2016 May 31;7(22):32329-40
pubmed: 27058624
Nature. 2014 Jul 10;511(7508):184-90
pubmed: 24930766
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Int Immunol. 2014 Jul;26(7):357-67
pubmed: 24402311
Front Immunol. 2019 May 07;10:890
pubmed: 31134053
Cancer Cell. 2003 Dec;4(6):437-50
pubmed: 14706336
Amino Acids. 2014 Sep;46(9):2155-63
pubmed: 24875753
Front Immunol. 2015 Feb 03;6:34
pubmed: 25691885
Nat Rev Immunol. 2019 Mar;19(3):184-197
pubmed: 30718831
J Am Coll Surg. 2009 May;208(5):781-7; discussion 787-9
pubmed: 19476837

Auteurs

Giada Mondanelli (G)

Department of Medicine and Surgery, Section of Pharmacology, University of Perugia, Perugia, Italy.

Martina Mandarano (M)

Department of Medicine and Surgery, Section of Anatomic Pathology and Histology, University of Perugia, Perugia, Italy.

Maria Laura Belladonna (ML)

Department of Medicine and Surgery, Section of Pharmacology, University of Perugia, Perugia, Italy.

Chiara Suvieri (C)

Department of Medicine and Surgery, Section of Pharmacology, University of Perugia, Perugia, Italy.

Cristina Pelliccia (C)

Department of Medicine and Surgery, Section of Anatomic Pathology and Histology, University of Perugia, Perugia, Italy.

Guido Bellezza (G)

Department of Medicine and Surgery, Section of Anatomic Pathology and Histology, University of Perugia, Perugia, Italy.

Angelo Sidoni (A)

Department of Medicine and Surgery, Section of Anatomic Pathology and Histology, University of Perugia, Perugia, Italy.

Agostinho Carvalho (A)

Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
ICVS/3B's - PT Government Associate Laboratory, Braga/Guimarães, Portugal.

Ursula Grohmann (U)

Department of Medicine and Surgery, Section of Pharmacology, University of Perugia, Perugia, Italy.

Claudia Volpi (C)

Department of Medicine and Surgery, Section of Pharmacology, University of Perugia, Perugia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH